ArticleHuman vaccines & immunotherapeutics2025
Rubella immunization policy in Japan: Immunity gaps arising from program differences and inconsistent cutoff standards.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rubella elimination remains a global health priority due to the risk of congenital rubella syndrome (CRS) following maternal infection during early pregnancy. Japan's immunization policy began in 1977 with female-only vaccination, reflecting a narrow focus on CRS prevention, and gradually expanded to universal childhood immunization. However, men born between 1962 and 1978-the so-called "lost generation" - were left with few vaccination opportunities, leading to major outbreaks in 2012-2013 and 2018-2019. In response, the government introduced the Phase 5 catch-up program in 2019, while women planning pregnancy and their partners were addressed through the CRS prevention program, which applies stricter serological cutoffs. Our single-institution data illustrate how program design and inconsistent cutoff standards generate apparent immunity gaps: the Phase 5 cohort showed seropositivity rates consistent with national surveys, whereas the CRS cohort revealed unexpectedly low immunity, particularly among young women. Applying a unified cutoff reduced these differences, underscoring the influence of threshold setting and participant selection. Japan's experience highlights the need to harmonize standards, strengthen interventions among young women, and sustain adult surveillance. More broadly, it offers international lessons on how policy design and inconsistent criteria can shape the assessment of immunity and the success of elimination strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.